LIMNWHIGH SIGNALFINANCIAL10-Q

LIMNW completed a significant equity financing transaction that dramatically improved its balance sheet position, reducing total liabilities by over 70% and substantially improving stockholders' equity from deeply negative territory.

The company appears to have executed a major recapitalization that addressed severe financial distress, moving stockholders' equity from -$8.8M to -$1.6M while dramatically reducing liabilities. However, the company maintains a substantial accumulated deficit of $30.7M and continues generating operating losses, indicating ongoing fundamental business challenges despite the balance sheet improvement.

Comparing 2025-11-14 vs 2025-10-06View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reflect a major balance sheet restructuring, with total liabilities declining dramatically from $10.7M to $3.0M and stockholders' equity improving substantially though remaining negative. Operating performance shows some improvement with R&D expenses halved and operating losses moderating, but the company continues burning cash with only $724K remaining. The overall picture suggests a distressed company that secured emergency financing to avoid immediate collapse but faces ongoing operational challenges.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+81.3%
-$8.8M-$1.6M

Equity base grew 81.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-72.8%
$10.5M$2.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-72.1%
$10.7M$3.0M

Liabilities reduced 72.1% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-50%
$714K$357K

R&D spending cut 50% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+37.3%
-$1.1M-$701K

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
-32.5%
$1.8M$1.2M

Current assets declined 32.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-29.7%
$1.9M$1.3M

Total assets contracted 29.7% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-11-14
PRIOR — 2025-10-06
ADDED
On July 1, 2025, the Company issued the shares to the underwriters, which on July 1, 2025 had a fair value of $ 7,245,000 .
The deficiency letter had no immediate effect on the listing of the Company s common stock, and its common stock continued to trade on Nasdaq under the symbol LIMN .
On October 6, 2025, the Company filed its Form 10-Q for the period ended June 30, 2025 and the matter was closed.
As of September 30, 2025, the Company had $ 724,502 of cash in its bank accounts.
The Company has an accumulated deficit of $ 30,702,806 as of September 30, 2025.
+7 more — sign up free →
REMOVED
Employer Identification No.) 6 Centerpointe Drive #625 , La Palma , CA 90623 (Address of principal executive offices, including zip code) ( 213 ) 273-5453 (Registrant s telephone number, including area code) Liminatus Pharma, Inc.
(SUCCESSOR TO IRIS PARENT HOLDING CORP.) NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1.
As of June 30, 2025, the shares remained unissued and the value of the Company s liability for the unissued shares is $ 7,805,000 , recorded in Deferred underwriting fee common stock payable on the accompanying unaudited condensed consolidated balance sheet.
On July 1, 2025, the Company issued the shares to the underwriters.
The Company has an accumulated deficit of $ 28,879,455 as of June 30, 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →